We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.
- Authors
Craft, J Carl; Moriarty, Susan R; Clark, Kay; Scott, Drusilla; Degenhardt, Thorsten P; Still, J Gordon; Corey, G Ralph; Das, Anita; Fernandes, Prabhavathi
- Abstract
Fusidic acid (CEM-102), an orally bioavailable fusidane antibiotic with a unique mode of action, is under development for treatment of acute gram-positive bacterial skin and skin structure infections, including those caused by methicillin-susceptible and methicillin-resistant Staphylococcus aureus and streptococci. A phase 2, adaptive design, randomized, double-blind, multiple-center study of 198 adult patients with cellulitis or wound infections was conducted to evaluate an oral CEM-102 loading-dose regimen (1500 mg twice per day on day 1 followed by 600 mg twice per day) compared with oral linezolid (600 mg twice per day) administered for 10-14 days. The CEM-102 loading-dose regimen demonstrated efficacy, safety, and tolerability that was comparable to linezolid for the treatment of acute gram-positive bacterial skin and skin structure infections. Clinical Trials registration. NCT00948142.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Vol 52 Suppl 7, pS520
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1093/cid/cir167